Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02379585 · ClinicalTrials.gov registry record · Phase 1
Fasting on Newly Diagnosed Breast Cancer
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02379585: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02379585 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02379585, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.
Interventions
- DRUG Trastuzumab
- DRUG Doxorubicin
- DRUG cyclophosphamide
- DRUG docetaxel
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02379585
The ClinicalTrials.gov registry entry for NCT02379585 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02379585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02379585 about?
NCT02379585 is a clinical study titled "Fasting on Newly Diagnosed Breast Cancer". This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.
What is the current status of trial NCT02379585?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02379585?
The interventions under investigation include: Trastuzumab (DRUG), Doxorubicin (DRUG), cyclophosphamide (DRUG), docetaxel (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02379585?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.